Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2020 1
2021 8
2022 8
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
[Digital transformation of COVID-19 research].
Park H, Woo JH, Iwanami S, Iwami S. Park H, et al. Among authors: iwanami s. Uirusu. 2022;72(1):39-46. doi: 10.2222/jsv.72.39. Uirusu. 2022. PMID: 37899228 Free article. Japanese.
Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir.
Torii S, Kim KS, Koseki J, Suzuki R, Iwanami S, Fujita Y, Jeong YD, Ito J, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato K, Matsuura Y, Shimamura T, Iwami S, Fukuhara T. Torii S, et al. Among authors: iwanami s. PLoS Pathog. 2023 Mar 27;19(3):e1011231. doi: 10.1371/journal.ppat.1011231. eCollection 2023 Mar. PLoS Pathog. 2023. PMID: 36972312 Free PMC article.
Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments.
Akazawa D, Ohashi H, Hishiki T, Morita T, Iwanami S, Kim KS, Jeong YD, Park ES, Kataoka M, Shionoya K, Mifune J, Tsuchimoto K, Ojima S, Azam AH, Nakajima S, Park H, Yoshikawa T, Shimojima M, Kiga K, Iwami S, Maeda K, Suzuki T, Ebihara H, Takahashi Y, Watashi K. Akazawa D, et al. Among authors: iwanami s. J Infect Dis. 2023 Aug 31;228(5):591-603. doi: 10.1093/infdis/jiad058. J Infect Dis. 2023. PMID: 36892247 Free PMC article.
A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19.
Miyazaki T, Hosogaya N, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Ozawa Y, Shiko Y, Inaba Y, Kurokawa T, Hanaoka H, Iwanami S, Kim K, Iwami S, Watashi K, Miyazawa K, Umeyama T, Yamagoe S, Miyazaki Y, Wakita T, Sumiyoshi M, Hirayama T, Izumikawa K, Yanagihara K, Mukae H, Kawasuji H, Yamamoto Y, Tarumoto N, Ishii H, Ohno H, Yatera K, Kakeya H, Kichikawa Y, Kato Y, Matsumoto T, Saito M, Yotsuyanagi H, Kohno S. Miyazaki T, et al. Among authors: iwanami s. Microbiol Spectr. 2023 Jun 15;11(3):e0431122. doi: 10.1128/spectrum.04311-22. Epub 2023 May 4. Microbiol Spectr. 2023. PMID: 37140398 Free PMC article. Clinical Trial.
Antithetic effect of interferon-α on cell-free and cell-to-cell HIV-1 infection.
Kumata R, Iwanami S, Mar KB, Kakizoe Y, Misawa N, Nakaoka S, Koyanagi Y, Perelson AS, Schoggins JW, Iwami S, Sato K. Kumata R, et al. Among authors: iwanami s. PLoS Comput Biol. 2022 Apr 25;18(4):e1010053. doi: 10.1371/journal.pcbi.1010053. eCollection 2022 Apr. PLoS Comput Biol. 2022. PMID: 35468127 Free PMC article.
Designing isolation guidelines for COVID-19 patients with rapid antigen tests.
Jeong YD, Ejima K, Kim KS, Joohyeon W, Iwanami S, Fujita Y, Jung IH, Aihara K, Shibuya K, Iwami S, Bento AI, Ajelli M. Jeong YD, et al. Among authors: iwanami s. Nat Commun. 2022 Aug 20;13(1):4910. doi: 10.1038/s41467-022-32663-9. Nat Commun. 2022. PMID: 35987759 Free PMC article.
Revisiting the guidelines for ending isolation for COVID-19 patients.
Jeong YD, Ejima K, Kim KS, Iwanami S, Bento AI, Fujita Y, Jung IH, Aihara K, Watashi K, Miyazaki T, Wakita T, Iwami S, Ajelli M. Jeong YD, et al. Among authors: iwanami s. Elife. 2021 Jul 27;10:e69340. doi: 10.7554/eLife.69340. Elife. 2021. PMID: 34311842 Free PMC article.
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
Ohashi H, Hishiki T, Akazawa D, Kim KS, Woo J, Shionoya K, Tsuchimoto K, Iwanami S, Moriyama S, Kinoshita H, Yamada S, Kuroda Y, Yamamoto T, Kishida N, Watanabe S, Hasegawa H, Ebihara H, Suzuki T, Maeda K, Fukushi S, Takahashi Y, Iwami S, Watashi K. Ohashi H, et al. Among authors: iwanami s. Antiviral Res. 2022 Sep;205:105372. doi: 10.1016/j.antiviral.2022.105372. Epub 2022 Jul 4. Antiviral Res. 2022. PMID: 35798223 Free PMC article.
23 results